24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
ADHD
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:43
Full list of Israeli high-tech layoffs in 2025
13:38
Hydrogen startup Electriq Global collapses under nearly $30M in debt, despite raising $25M
11:26
PwC integrates altshare’s algorithm to streamline startup valuations
14:27
Nice beats Q4 estimates but shares plunge on weak 2025 outlook
More stories
Buzz
Most popular
Daily
Weekly
1
Insight Partners hit by cyber attack with possible data leaks
2
CyberArk’s surge, Wiz and Cato prepare for IPOs: Israeli cyber firms ready for the next big move
3
Cybereason CEO accuses Mnuchin, SoftBank of forcing company toward bankruptcy
4
Israel-China tech ties persist amid political tensions
5
Riskified cuts staff as struggles continue
More news
ADHD
4 stories about ADHD
“There are so few female founders; this has to be put in the past”
21.08.24
|
Ariela Karmel
Eve Mamane, Co-Founder and CRO of mental health startup Agave Health, spoke to CTech about founding her first venture, the need to normalize female founders, and why the tech industry must eliminate outdated limitations on women in leadership roles
Israeli app launches in the U.S. and Israel, helping parents of ADHD children
15.01.24
|
James Spiro
Pery uses clinical data and LLMs to provide advice and analysis for parents managing children diagnosed with attention deficit hyperactivity disorder
“There is a $5 billion opportunity in the ADHD market”
30.01.23
|
CTech
MindTension has raised a total of $2 million for its tool helping diagnose and treat optimization of ADHD and related mental health comorbidities
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026